Related Experiment Videos
Treatment with alpha-interferon in chronic hepatitis
I Matei1, C Tănăsescu, R Voiosu
1N. Gh. Lupu Clinical Hospital, Bucharest, Romania.
Summary
Interferon treatment for chronic viral hepatitis shows varying responses. This study examines alpha-Interferon efficacy using alanine-aminotransferase (ALAT) and aspartate-aminotransferase (ASAT) markers in a 6-month regimen.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Interferon therapy is a key treatment for chronic viral hepatitis.
- Existing literature presents conflicting data on optimal Interferon dosage and treatment duration.
- Numerous markers are proposed for assessing treatment response and predicting efficacy.
Purpose of the Study:
- To evaluate the response to alpha-Interferon in a standard 6-month treatment regimen.
- To assess the efficacy of alpha-Interferon in patients with chronic hepatitis B, chronic hepatitis C, and co-infection.
- To utilize alanine-aminotransferase (ALAT) and aspartate-aminotransferase (ASAT) as primary markers for treatment response.
Main Methods:
- A 6-month treatment regimen of alpha-Interferon was administered.
- Patients with chronic hepatitis B, chronic hepatitis C, and co-infection were included.
- Treatment response was monitored using serum levels of ALAT and ASAT.
Main Results:
- The study analyzed treatment responses based on ALAT and ASAT levels.
- Specific outcomes regarding the efficacy of the 6-month regimen were determined.
- Data on marker changes provided insights into patient responses.
Conclusions:
- The 6-month alpha-Interferon regimen's effectiveness was assessed using liver enzyme markers.
- Findings contribute to understanding Interferon therapy for chronic viral hepatitis B and C.
- ALAT and ASAT serve as crucial indicators for evaluating treatment outcomes.